TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00660101

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: OVax: Autologous, DNP-Modified Ovarian Cancer Vaccine
Description: OVax: Autologous, DNP-Modified Ovarian Cancer Vaccine cells in suspension dosage - depends on arm route - intradermal frequency - weekly x7, booster at 6 months

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: OVax: Autologous, DNP-Modified Ovarian Cancer Vaccine
Description: OVax: Autologous, DNP-Modified Ovarian Cancer Vaccine cells in suspension dosage - depends on arm route - intradermal frequency - weekly x7, booster at 6 months

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: OVax: Autologous, DNP-Modified Ovarian Cancer Vaccine
Description: OVax: Autologous, DNP-Modified Ovarian Cancer Vaccine cells in suspension dosage - depends on arm route - intradermal frequency - weekly x7, booster at 6 months
Study: NCT03382483

Intervention type: DEVICE
Intervention: Low intensity pulsed ultrasound
Description: bone growth stimulator
Study: NCT00661700

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levitra (Vardenafil, BAY38-9456)
Description: 10mg Vardenafil for 4 weeks followed by an 8 week titration period when subjects may be titrated up to 20mg Vardenafil or down to 5mg Vardenafil followed by 14 weeks treatment at preferred dose.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 10mg placebo for 4 weeks followed by an 8 week titration period when subjects may be titrated up to 20mg placebo or down to 5mg placebo followed by 14 weeks placebo at preferred dose
Study: NCT01428193

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Flutamide
Description: Subjects weighing \> 50 kg will receive 250 mg orally twice a day, and subjects weighing \< 50 kg will receive 125 mg orally twice a day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Progesterone
Description: oral progesterone suspension (20 mg/ml, 25-100 mg) three times a day at 0700, 1500, and 2300 hr for seven days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: estrace
Description: 0.5-1 mg once a day for seven days
Study: NCT03523117

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ferric carboxymaltose
Description: Intravenous iron

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ferrous Sulfate
Description: oral iron therapy
Study: NCT03751085

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AW frame
Description: AW stereotactic frame for intracranial lesion biopsy
Study: NCT00984581

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avotermin
Description: Intradermal injection, 5ng/100ul/linear cm wound margin administered on Day 0, Day 1 and month 6

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avotermin
Description: Intradermal injection, 50ng/100ul/linear cm wound margin administered on Day 0, Day 1 and month 6

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intradermal injection, 100ul/linear cm wound margin administered on Day 0 and Day 1
Study: NCT02377089

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Trigeminal Nerve Stimulation
Description: Subjects will be randomized to treatment with either active or sham TNS for a period of eight weeks. The programming will be set by an individual who has no contact with subjects to deliver TNS in a double-blind manner (n=37 in each group) at the active frequency of 120 Hz. TNS will be performed for approximately 8 hours each night, a protocol that subjects found acceptable in the pilot work.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Placebo
Description: Subjects will be randomized to treatment with either active or sham TNS for a period of eight weeks. The programming will be set by an individual who has no contact with subjects to deliver TNS in a double-blind manner (n=37 in each group) at the sham frequency of 0 Hz. TNS will be performed for approximately 8 hours each night, a protocol that subjects found acceptable in the pilot work.
Study: NCT03584269

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NIV Device + LTOT
Description: Respiratory assistance by a facial mask without intubation or tracheotomy
Study: NCT04287036

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: JJVC Investigational Contact Lens
Description: TEST

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: JJVC Investigational Contact Lens
Description: TEST

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 1-DAY ACUVUE® DEFINE® Radiant Sweet™
Description: CONTROL

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 1-DAY ACUVUE® DEFINE® Radiant Sweet™
Description: CONTROL
Study: NCT02880293

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: melphalan
Description: melphalan (140 mg/m2 IV on day -7)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fludarabine
Description: fludarabine (40 mg/m2/d on days -5 through -2)
Study: NCT04249557

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: exercise is medicine
Description: a 12-week exercise classes program combined with other motivational skills, including feedback and information technology support. The whole program lasts for 1 year for each participant
Study: NCT04423107

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetaminophen, Ibuprofen
Description: Acetaminophen (Tylenol) 15 mg/kg q6h and Ibuprofen (10 mg/kg) q6h

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetaminophen, Ibuprofen, Oxycodone
Description: Acetaminophen (Tylenol) 15 mg/kg q6h, Ibuprofen q6h, and Oxycodone 0.1 mg/kg q6h
Study: NCT01300312

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eperisone hydrochloride and Diclofenac sodium
Description: Fixed dose capsule formulation of eperisone hydrochloride 50 mg plus diclofenac sodium 50 mg to be given 3 times a day after meals for 7 to 10 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Eperisone hydrochloride
Description: eperisone hydrochloride 50 mg as tablet formulation to be given 3 times daily after meals for 7 to 10 days
Study: NCT02267174

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Standardized handoff
Description: A standardized handoff will be implemented that consists of choreographed handoffs utilizing a structured handoff tool to facilitate information exchange.
Study: NCT02880293

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: thiotepa
Description: thiotepa (5 mg/kg IV on day -67)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: cyclophosphamide (50 mg/kg IV on day +3 and +4)
Study: NCT00239928

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pegaptanib sodium
Description: 1 drop per dosed eye per protocol.
Study: NCT01440088

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TH-302 in Combination with Doxorubicin
Description: 300 mg/m2 of TH-302 will be administered by IV infusion over 30-60 minutes on Days 1 and 8 of a 21-day cycle.~Doxorubicin may be delivered as a bolus administration or as a continuous infusion administration; administration schedule must be specified prior to enrollment.~Doxorubicin bolus administration: 75 mg/m2 administered by bolus injection starting on Day 1 of a 21-day cycle.~Doxorubicin continuous administration: 75 mg/m2 administered by continuous IV infusion over 48-96 hours starting on Day 1 of a 21-day cycle.~Doxorubicin administration will start between 2 to 4 hours after completion of the TH-302 infusion when used in combination with TH-302.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxorubicin
Description: Doxorubicin may be delivered as a bolus administration or as a continuous infusion administration; administration schedule must be specified prior to enrollment.~Doxorubicin bolus administration: 75 mg/m2 administered by bolus injection starting on Day 1 of a 21-day cycle.~Doxorubicin continuous administration: 75 mg/m2 administered by continuous IV infusion over 48-96 hours starting on Day 1 of a 21-day cycle.
Study: NCT04043559

Intervention type: OTHER
Intervention: MRI scanner
Description: MRI was performed with a 1.5T magnet (Ingenia, Philips, The Netherlands; diffusion-weighted imaging b-values = 0 and 1,000 s/mm2, TR 4,280 ms, and TE 97 ms). In case of technical problems with the 1.5T MRI scanner, a 3T magnet (Skyra, Siemens, Erlangen, Germany) was used. MRI was analyzed by an experienced rater (DR), blinded to clinical data and MRI sequences other than diffusion-weighted imaging.

Intervention type: OTHER
Intervention: MRI scanner
Description: MRI was performed with a 1.5T magnet (Ingenia, Philips, The Netherlands; diffusion-weighted imaging b-values = 0 and 1,000 s/mm2, TR 4,280 ms, and TE 97 ms). In case of technical problems with the 1.5T MRI scanner, a 3T magnet (Skyra, Siemens, Erlangen, Germany) was used. MRI was analyzed by an experienced rater (DR), blinded to clinical data and MRI sequences other than diffusion-weighted imaging.

Intervention type: OTHER
Intervention: Contrast transoesophageal echocardiography
Description: Contrast transoesophageal echocardiography (including Valsalva manoeuvre)
Study: NCT02880293

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mesna

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil
Description: (15 mg/kg PO/IV TID)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Filgrastim

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Study: NCT02031601

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Description: 150mg po once a day on days 2-15 of each 3 week cycle for 4 cycles; then continue to receive erlotinib150mg po once a day daily until progression

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gefitinib
Description: 250mg po once a day on days 2-15 of each 3 week cycle for 4 cycles; then continue to receive gefitinib 250mg po once a day daily until progression

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Icotinib
Description: 125mg po three time a day on days 2-15 of each 3 week cycle for 4 cycles; then continue to receive icotinib 125mg po three time a day daily until progression

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: 75 mg/m2 ivgtt on days 1 of each 3 week cycle for 4 cycles
Study: NCT02976961

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Supportive care
Description: Information, guidance, supportive care, and psychological intervention
Study: NCT04057300

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor 90mg
Description: Ticagrelor tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel 75mg
Description: Clopidogrel tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: acetylsalicylic acid (ASA) 81mg
Description: acetylsalicylic acid tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: acetylsalicylic acid (ASA) 81mg
Description: acetylsalicylic acid tablet
Study: NCT03188978

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin 40mg
Description: one 40mg tablet daily for 8 weeks starting 2 weeks before the AVF creation.
Study: NCT02031601

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: 500 mg/m2 ivgtt on days 1 of each 3 week cycle for 4 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Platinum (cisplatin or carboplatin)
Description: cisplatin -- 75mg/m2 ivgtt on day 1 of each 3 week cycle for 4 cycles or carboplatin -- 5 x AUC ivgtt on day 1 of each 3 week cycle for 4 cycles
Study: NCT03188978

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: one tablet daily for 8 weeks starting 2 weeks before the AVF creation.
Study: NCT02031601

Intervention type: DRUG
Group type: OTHER
Intervention: Erlotinib
Description: 150mg po once a day daily until disease progression
Study: NCT04004520

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual Reality with Meditation
Description: The Guided Meditation Virtual Reality is a mindfulness meditation app provided on a virtual reality platform that includes a 10 minute audio meditation for relaxation along with a 3D visualization of natural settings (e.g. forest, beach, mountain).

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Audio Control
Description: The UCLA Mindful App is an audio only mindfulness meditation for relaxation called Breath, Sound, Body Meditation that is 12 minutes in length.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Virtual reality Control
Description: The Looking Glass Virtual Reality is a stereographic 3D photo viewer provided on a virtual reality platform featuring photos from around the world dating back to approximately a century ago that participants will view for 10 minutes.
Study: NCT00324363

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: exenatide
Description: subcutaneous injection, 5mcg or 10mcg, twice a day for 16 weeks
Study: NCT02031601

Intervention type: DRUG
Group type: OTHER
Intervention: Gefitinib
Description: 250mg po once a day daily until disease progression
Study: NCT00324363

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: subcutaneous injection twice daily in volumes equal to exenatide
Study: NCT03684772

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ICVT Topical Gel
Description: Digoxin and Furosemide (0.125%)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Furosemide Topical Gel
Description: Furosemide (0.125%)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Digoxin Topical Gel
Description: Digoxin (0.125%)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle Topical Gel
Description: Vehicle Gel
Study: NCT00279409

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: aripiprazole
Description: double blind capsules (abilify or placebo) taken once daily, up to 10mg.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sugar pill
Description: double blind capsules (abilify or placebo) taken once daily, up to 10mg.
Study: NCT04043559

Intervention type: OTHER
Intervention: Contrast transoesophageal echocardiography
Description: Contrast transoesophageal echocardiography (including Valsalva manoeuvre)
Study: NCT03263273

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 1% Topical Minocycline Gel
Description: Treating Papulopustular Rosacea while monitoring for safety and efficacy of the active intervention

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 3% Topical Minocycline Gel
Description: Treating Papulopustular Rosacea while monitoring for safety and efficacy of the active intervention

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Topical Vehicle Gel
Description: Treating Papulopustular Rosacea while monitoring for safety and efficacy of the vehicle intervention
Study: NCT02134860

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Bed rest
Description: 8 days of full bed rest

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Bed rest
Description: 8 days of full bed rest

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: OGTT
Description: Oral glucose tolerance test with 75 g of glucose before and after bed rest

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: OGTT
Description: Oral glucose tolerance test with 75 g of glucose before and after bed rest

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: IVGTT
Description: Intravenous glucose tolerance test mimicking the glucose profile from the corresponding OGTT

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: IVGTT
Description: Intravenous glucose tolerance test mimicking the glucose profile from the corresponding OGTT

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive testing
Description: Daily testing of memory and concentration using standardized tests

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive testing
Description: Daily testing of memory and concentration using standardized tests

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Muscle and fat biopsies
Description: Biopsies will be obtained before and after bed rest

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Muscle and fat biopsies
Description: Biopsies will be obtained before and after bed rest
Study: NCT03957759

Intervention type: DIAGNOSTIC_TEST
Intervention: Structured self-monitoring during an altitude ascent and stay at high altitude
Description: Structured self-monitoring by a symptom checklist in combination with a pulse oximeter worn at the wrist in lowlanders with COPD ascending from low altitude (760m) to high altitude (3100m).
Study: NCT03872661

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IBI308
Description: IBI308 was given 200 mg iv infusion on day 1 of each 21-day cycle for 4 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab was administered at a dose of 15 mg/kg on day 1 of each 21-day cycle for 4 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Pemetrexed was given 500 mg/m\^2 i.v. injection on day 1 of each 21-day cycle for 4 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin was given dosed to an area under the serum concentration-time curve (AUC) of 5 i.v. on day 1 of each 21-day cycle for 4 cycles.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Thoracic surgery
Description: Surgery will be performed at least 21 days after the last dose of neoadjuvant therapy.
Study: NCT04593004

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Teledermatology
Description: Patients will be assessed and followed-up by trained physicians through a store-and-forward system (teledermatology online service - Evita® app), which allows patients to upload pictures of skin areas affected by acne as well as their symptoms or questions related to their disease.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Face-to-face consultation
Description: Patients will be assessed and followed-up by trained physicians through regular face-to-face outpatient consultations.
Study: NCT02031601

Intervention type: DRUG
Group type: OTHER
Intervention: Icotinib
Description: 125mg po three times a day daily until disease progression
Study: NCT05472480

Intervention type: DIAGNOSTIC_TEST
Intervention: anthropometric and psychosocial measurements
Description: Different types of measurements will be evaluated: body mass index (BMI), weight, height, waist circumference, waist / hip ratio (WHR), waist / stature (WSR) and the ABSI a body score shape index . To complete the study, the personal experiences of the patients will be analyzed through the administration of a psycho-social questionnaire, Body Image Disturbance Questionnaire (BIDQ).

Intervention type: DIAGNOSTIC_TEST
Intervention: anthropometric and psychosocial measurements
Description: Different types of measurements will be evaluated: body mass index (BMI), weight, height, waist circumference, waist / hip ratio (WHR), waist / stature (WSR) and the ABSI a body score shape index . To complete the study, the personal experiences of the patients will be analyzed through the administration of a psycho-social questionnaire, Body Image Disturbance Questionnaire (BIDQ).

Intervention type: DIAGNOSTIC_TEST
Intervention: anthropometric and psychosocial measurements
Description: Different types of measurements will be evaluated: body mass index (BMI), weight, height, waist circumference, waist / hip ratio (WHR), waist / stature (WSR) and the ABSI a body score shape index . To complete the study, the personal experiences of the patients will be analyzed through the administration of a psycho-social questionnaire, Body Image Disturbance Questionnaire (BIDQ).

Intervention type: DIAGNOSTIC_TEST
Intervention: anthropometric and psychosocial measurements
Description: Different types of measurements will be evaluated: body mass index (BMI), weight, height, waist circumference, waist / hip ratio (WHR), waist / stature (WSR) and the ABSI a body score shape index . To complete the study, the personal experiences of the patients will be analyzed through the administration of a psycho-social questionnaire, Body Image Disturbance Questionnaire (BIDQ).
Study: NCT03495765

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ranibizumab
Description: Ranibizumab 0.5mcg via intravitreal injection to study eye up to monthly
Study: NCT02134860

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Dual-energy X-ray Absorptiometry (DXA) scan
Description: DXA scan to evaluate fat and muscle distribution before and after bed rest
Study: NCT02134860

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Dual-energy X-ray Absorptiometry (DXA) scan
Description: DXA scan to evaluate fat and muscle distribution before and after bed rest

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: MRI
Description: Functional MRI to evaluate cognitive function and abdominal MRI to evaluate visceral fat before and after bed rest
Study: NCT01278381

Intervention type: PROCEDURE
Intervention: Pancreaticoduodenectomy
Description: Resection of pancreatic lesion
Study: NCT03711747

Intervention type: PROCEDURE
Intervention: Osteochondral allograft ankle
Description: Open osteochondral allograft to replace the cartilage that is grade four on the tibia and/or talus
Study: NCT00578448

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Belatacept
Description: IV infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Belatacept
Description: IV infusion
Study: NCT02279472

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Laserex Tango Nd:YAG, Ellex-SuperQ Medical, Australia
Description: All the patients will be achieved with pilocarpine 1% for pupil constriction, laser peripheral iridotomy(LPI) is performed using the ophthalmic neodymium: yttrium aluminium garnet laser (Laserex Tango Nd:YAG, Ellex-SuperQ Medical, Australia) and an VOLK iridotomy contact lens. After LPI, patients will be given topical prednisolone acetate 0.1% for 7 days.
Study: NCT06192875

Intervention type: OTHER
Intervention: Non-Interventional Study
Description: Non-interventional study
Study: NCT00883129

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil
Description: 24 months of oral mycophenolate mofetil, up to a maximal dose of 1.5 grams twice daily as tolerated

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 12 months of oral cyclophosphamide, up to a maximal dose of 2 mg/kg daily as tolerated

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 12 months of placebo will be delivered to participants in the Cyclophosphamide arm during the second year in order to maintain the blind with the Mycophenolate arm, which receives drug for the entire 2 years.
Study: NCT00862667

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment A
Description: PF-00241939 300ug using Inhaler A

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Treatment B
Description: PF-00241939 300ug using Inhaler B

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Treatment C
Description: PF-00241939 300ug using Inhaler C